Drug Trial Radar · NCT02194985
Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Last checked: Nov 19, 2026Latest source record: Dec 21, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
84
Actual
Start
Mar 14, 2015
Primary completion
Oct 23, 2019
Study completion Oct 23, 2019
Sponsor
- Lead sponsor
- Amicus TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 21, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study intended to provide continued treatment with migalastat hydrochloride (HCl) for participants with Fabry disease who completed treatment of a previous migalastat HCl study. The study assessed the long-term safety and effectiveness of migalastat HCl.
Conditions
- Fabry Disease
Interventions
migalastat HCl 150 mgDrug
Migalastat HCl 150 mg (equivalent to 123 mg migalastat) was provided as capsules in blister packs. One capsule was taken orally every other day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number Of Participants Experiencing Adverse Events (AEs)Time frame: Day 1 after first dose to approximately 30 days after last treatment, median duration of 3.1 years
Locations
28 sites in 15 countries. Site status is shown where the registry gives one.
Clinical Study Site
Atlanta, Georgia
Clinical Study Site
Kansas City, Kansas
Clinical Study Site
Grand Rapids, Michigan
Clinical Study Site
New York, New York
Clinical Study Site
Portland, Oregon
Clinical Study Site
Dallas, Texas
Clinical Study Site
Fairfax, Virginia
Clinical Study Site
Pilar, Argentina
Clinical Study Site
Adelaide, Australia
Clinical Study Site
Parkville, Australia
Clinical Study Site
Vienna, Austria
Clinical Study Site
Edegem, Belgium
Clinical Study Site
Porto Alegre, Brazil
Clinical Study Site
Montreal, Quebec, Canada
Clinical Study Site
Copenhagen, Denmark
Clinical Study Site
Cairo, Egypt
Clinical Study Site
Garches, France
Clinical Study Site
Lille, France
Clinical Study Site
Florence, Italy
Clinical Study Site
Roma, Italy
Clinical Study Site
Niigata, Japan
Clinical Study Site
Osaka, Japan
Clinical Study Site
Tokyo, Japan
Clinical Study Site
Suita, Osaka, Japan
Clinical Study Site
Barcelona, Spain
Clinical Study Site
Ankara, Turkey (Türkiye)
Clinical Study Site
London, United Kingdom
Clinical Study Site
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.